Andres Lopez-Albaitero MD
Head & Neck Oncologic Surgery
Otolaryngology / ENT and Allergy
Join to view full profile
2818 31st StFl 2Astoria, NY 11102
Phone+1 718-971-2490
Fax+1 718-971-2489
Dr. Lopez-Albaitero is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Andres Lopez-Albaitero is an otolaryngologist in Astoria, NY and is affiliated with multiple hospitals in the area, including Mount Sinai Queens. He received his medical degree from Universidad La Salle School of Medicine. He is experienced in general otolaryngology, head and neck oncology, thyroid surgery, and head and neck surgery.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Clinical Scholar, 2012 - 2015
UPMC Medical Education (Pittsburgh)Residency, Otolaryngology - Head and Neck Surgery, 2005 - 2012
Universidad La Salle School of MedicineClass of 2000
Certifications & Licensure
NH State Medical License 2014 - Present
NJ State Medical License 2024 - 2027
NY State Medical License 2012 - 2027
TX State Medical License 2020 - 2026
MA State Medical License 2013 - 2016
PA State Medical License 2005 - 2012
American Board of Otolaryngology - Head and Neck Surgery Otolaryngology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2017
Publications & Presentations
PubMed
- 40 citationsTCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.Mahiuddin Ahmed, Andres Lopez-Albaitero, Dmitry Pankov, Brian H. Santich, Hong Liu
JCI Insight. 2018-02-22 - 66 citationsOvercoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibodyAndres Lopez-Albaitero, Hong Xu, Hong-fen Guo, Linlin Wang, Zhihao Wu
Oncoimmunology. 2017-03-10 - 255 citationsCetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer PatientsRaghvendra M. Srivastava, Steve C. Lee, Pedro A. Andrade Filho, Christopher A. Lord, Hyun-Bae Jie
Clinical Cancer Research. 2013-04-01
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
